Page 1

Merck Hosts Organon Investor Day Outlining New Company's Vision , Focus and Business Model for Sustained Growth May 3 , 2021 6:45 am EDT Save Print Standalone company positioned to deliver low to mid - single digit revenue growth off 2021 base ⚫ Future growth opportunities include Women's Health and Biosimilars businesses ; Established Brands portfolio expected to provide significant cash flow to invest in new opportunities , with modest future LOE risk after 2021 • Organon will have a diverse product portfolio with no product representing more than 11 % of total revenue , and an expansive global geographic footprint with nearly 80 % of revenue generated outside the U.S. • Experienced management team and majority - female Board of Directors focused on the vision to create a better and healthier every day for every woman around the globe ⚫ Organon will begin regular way trading on the New York Stock Exchange under ticker symbol " OGN " on June 3 KENILWORTH , N.J .- ( BUSINESS WIRE ) -Merck ( NYSE : MRK ) , known as MSD outside the United States and Canada , today will host Organon management at a meeting with the investment community . Management will detail plans for how Organon is expected to drive sustainable growth and shareholder value as a standalone company . " The spinoff of Organon will help Merck become a leaner , more focused and agile company with stronger growth , and will enable significant operating efficiencies . Organon , as a standalone company , will be better positioned to realize its potential and to have a meaningful impact , particularly in women's health " , said Rob Davis , president , Merck . " We believe this transaction will create value for the patients both